• Citer

Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib

par La Rosée, Paul;Klag, Thomas;Schenk, Thomas;Hochhaus, Andreas;Martiat, Philippe ;Leitner, Armin;Muller, Martin M.J.;Erben, Philipp;Saussele, Susanne
Référence Annals of hematology, 92, 10, page (1345-1350)
Publication Publié, 2013-10

Article révisé par les pairs

• Détails
• Contenu

Titre:	Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
Auteur:	La Rosée, Paul; Klag, Thomas; Schenk, Thomas; Hochhaus, Andreas; Martiat, Philippe; Leitner, Armin; Muller, Martin M.J.; Erben, Philipp; Saussele, Susanne
Informations sur la publication:	Annals of hematology, 92, 10, page (1345-1350)
Statut de publication:	Publié, 2013-10
Sujet CREF:	Hématologie
Mots-clés:	CML
	Dasatinib
	Dosing
	Resistance
	Tolerability
	Toxicity
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Benzamides -- administration & dosage -- therapeutic use
	Drug Administration Schedule
	Drug Resistance, Neoplasm
	Female
	Humans
	Leukemia, Myeloid, Chronic-Phase -- drug therapy
	Male
	Middle Aged
	Piperazines -- administration & dosage -- therapeutic use
	Pyrimidines -- administration & dosage -- therapeutic use
	Retrospective Studies
	Thiazoles -- administration & dosage -- therapeutic use
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0939-5555
	info:doi/10.1007/s00277-013-1769-2
	info:scp/84883891271
	info:pmid/23625298